The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Difenin     sodium5-oxo-4,4-diphenyl-1H- imidazol-2-olate

Synonyms:
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Difenin

 

Psychiatry related information on Difenin

 

High impact information on Difenin

 

Chemical compound and disease context of Difenin

 

Biological context of Difenin

  • The dilantin binding site is distinct from the Vinca binding site, and these independent binding modes account for the additive effects in vitro [21].
  • The authors examined the effect of food on the bioavailability of Dilantin Kapseals in a nonblinded, single 100-mg dose, randomized, crossover trial [22].
  • The pharmacokinetic profile of a newly developed Dilantin 300-mg Kapseal formulation was compared with that of currently marketed Dilantin 100-mg Kapseals in both a 300-mg single-dose bioequivalence study in nine healthy volunteers and a once-daily 300-mg multiple-dose study in 18 patients with seizures [23].
  • ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures [24].
  • The ACC-9653 and phenytoin sodium treatments produced similar marked reductions in diastolic blood pressure and contractile force (LVdP/dt) [6].
 

Anatomical context of Difenin

 

Associations of Difenin with other chemical compounds

 

Gene context of Difenin

 

Analytical, diagnostic and therapeutic context of Difenin

References

  1. Dilantin and the fragile X syndrome. Hagerman, R.J., Levitas, A. N. Engl. J. Med. (1983) [Pubmed]
  2. Landmark article Sept 17, 1938: Sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam. Merritt, H.H., Putnam, T.J. JAMA (1984) [Pubmed]
  3. Management of trigeminal neuralgia (tic douloureux). Voorhies, R., Patterson, R.H. JAMA (1981) [Pubmed]
  4. Status epilepticus. The role of intravenous phenytoin. Cloyd, J.C., Gumnit, R.J., McLain, L.W. JAMA (1980) [Pubmed]
  5. Removal of phenytoin by hemodialysis in uremic patients. Martin, E., Gambertoglio, J.G., Adler, D.S., Tozer, T.N., Roman, L.A., Grausz, H. JAMA (1977) [Pubmed]
  6. Pharmacology of ACC-9653 (phenytoin prodrug). Smith, R.D., Brown, B.S., Maher, R.W., Matier, W.L. Epilepsia (1989) [Pubmed]
  7. Facilitation of opiate- and enkephalin-induced motor activity in the mouse by phenytoin sodium and carbamazepine. Katz, R.J., Schmaltz, K. Psychopharmacology (Berl.) (1979) [Pubmed]
  8. Dilantin toxicity in a preterm infant: persistent bradycardia and lethargy. Wiriyathian, S., Kaojarern, S., Rosenfeld, C.R. J. Pediatr. (1982) [Pubmed]
  9. The management of idiopathic olfactory hallucinations: a study of two patients. Majumdar, S., Jones, N.S., McKerrow, W.S., Scadding, G. Laryngoscope (2003) [Pubmed]
  10. Specificity of treatment effects for learning disabilities in a boy prenatally exposed to dilantin. Weiner, T.S., Romanczyk, R.G., Donovick, P.J. Pediatric rehabilitation. (1998) [Pubmed]
  11. Phenytoin infusion in severe pre-eclampsia. Slater, R.M., Wilcox, F.L., Smith, W.D., Donnai, P., Patrick, J., Richardson, T., Mawer, G.E., D'Souza, S.W., Anderton, J.M. Lancet (1987) [Pubmed]
  12. Acute pulmonary disease caused by phenytoin. Michael, J.R., Rudin, M.L. Ann. Intern. Med. (1981) [Pubmed]
  13. Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium ingestion: the role of bile duct injury. Spechler, S.J., Sperber, H., Doos, W.G., Koff, R.S. Ann. Intern. Med. (1981) [Pubmed]
  14. Dilantin toxicity: miliary pulmonary infiltrates and hypoxemia. Bayer, A.S., Targan, S.R., Pitchon, H.E., Guze, L.B. Ann. Intern. Med. (1976) [Pubmed]
  15. Letter: Dilantin, agranulocytosis, and phagocytic marrow histiocytes. Tsan, M.F., Mehlman, D.J., Green, R.S., Bell, W.R. Ann. Intern. Med. (1976) [Pubmed]
  16. Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Hassell, T.M., Page, R.C., Narayanan, A.S., Cooper, C.G. Proc. Natl. Acad. Sci. U.S.A. (1976) [Pubmed]
  17. Specific estrogen receptors in human gingiva. Vittek, J., Hernandez, M.R., Wenk, E.J., Rappaport, S.C., Southren, A.L. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  18. Presenile cataracts in phenytoin-treated epileptic patients. Bar, S., Feller, N., Savir, H. Arch. Ophthalmol. (1983) [Pubmed]
  19. Nonketotic hyperglycemic hyperosmolar coma. Report of neurosurgical cases with a review of mechanisms and treatment. Park, B.E., Meacham, W.F., Netsky, M.G. J. Neurosurg. (1976) [Pubmed]
  20. Phenytoin and folic acid: individualized drug-drug interaction. Berg, M.J., Rivey, M.P., Vern, B.A., Fischer, L.J., Schottelius, D.D. Therapeutic drug monitoring. (1983) [Pubmed]
  21. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Lobert, S., Ingram, J.W., Correia, J.J. Cancer Res. (1999) [Pubmed]
  22. Effect of food on the bioavailability of 100-mg dilantin Kapseals. Cook, J., Randinitis, E., Wilder, B.J. Neurology (2001) [Pubmed]
  23. Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation. Randinitis, E.J., Buchanan, R.A., Kinkel, A.W. Epilepsia (1990) [Pubmed]
  24. ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. Van Drie, J.H., Weininger, D., Martin, Y.C. J. Comput. Aided Mol. Des. (1989) [Pubmed]
  25. Ionic basis of phenytoin sodium inhibition of insulin secretion in pancreatic islets. Pace, C.S., Livingston, E. Diabetes (1979) [Pubmed]
  26. Phenytoin and formation of T lymphocyte rosettes. Neilan, B.A., Leppik, I.E. Arch. Neurol. (1980) [Pubmed]
  27. Collagenolysis by human gingival fibroblast cell lines. Rose, G.G., Robertson, P.B. J. Dent. Res. (1977) [Pubmed]
  28. Microscopic assay for the phagocytotic-collagenolytic performance (PCP index) of human gingival fibroblasts in vitro. Rose, G.G., Yajima, T., Mahan, C.J. J. Dent. Res. (1978) [Pubmed]
  29. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. Magariños, A.M., McEwen, B.S., Flügge, G., Fuchs, E. J. Neurosci. (1996) [Pubmed]
  30. Effect of calcium and antacids on phenytoin bioavailability. Chapron, D.J., Kramer, P.A., Mariano, S.L., Hohnadel, D.C. Arch. Neurol. (1979) [Pubmed]
  31. Posttraumatic Amnesia as a predictor of outcome after severe closed head injury. Prospective assessment. Ellenberg, J.H., Levin, H.S., Saydjari, C. Arch. Neurol. (1996) [Pubmed]
  32. Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes. Herdon, H.J., Jerman, J.C., Stean, T.O., Middlemiss, D.N., Chan, W.N., Vong, A.K., Evans, J.M., Thompson, M., Upton, N. Br. J. Pharmacol. (1997) [Pubmed]
  33. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. Hong, H.H., Uzel, M.I., Duan, C., Sheff, M.C., Trackman, P.C. Lab. Invest. (1999) [Pubmed]
  34. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. Kupiec, T., Raj, V. Journal of analytical toxicology. (2005) [Pubmed]
  35. Paroxysmal kinesigenic choreoathetosis and abnormal contingent negative variation. A case report. Franssen, H., Fortgens, C., Wattendorff, A.R., van Woerkom, T.C. Arch. Neurol. (1983) [Pubmed]
  36. Putnam, Merritt, and the discovery of Dilantin. Friedlander, W.J. Epilepsia (1986) [Pubmed]
  37. Chemical requirements of vasopressins for barrel rotation convulsions and reversal by oxytocin. Abood, L.G., Knapp, R., Mitchell, T., Booth, H., Schwab, L. J. Neurosci. Res. (1980) [Pubmed]
  38. Phenytoin disposition in obesity. Determination of loading dose. Abernethy, D.R., Greenblatt, D.J. Arch. Neurol. (1985) [Pubmed]
  39. Stevens-Johnson syndrome and epidermal necrolysis after administration of sodium phenytoin with cranial irradiation. Janinis, J., Panagos, G., Panousaki, A., Skarlos, D., Athanasiou, E., Karpasitis, N., Pirounaki, M. Eur. J. Cancer (1993) [Pubmed]
  40. Phenytoin metabolism in the cat after long-term oral administration. Hassell, T.M., Maguire, J.H., Cooper, C.G., Johnson, P.T. Epilepsia (1984) [Pubmed]
  41. Serum phenytoin concentration and clinical response in patients with epilepsy. Gannaway, D.J., Mawer, G.E. British journal of clinical pharmacology. (1981) [Pubmed]
  42. Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. Cox, J.W., Sage, G.P., Wynalda, M.A., Ulrich, R.G., Larson, P.G., Su, C.C. Journal of pharmaceutical sciences. (1991) [Pubmed]
 
WikiGenes - Universities